Review

Association of fructose consumption and components of metabolic syndrome in human studies: A systematic review and meta-analysis

Roya Kelishadi M.D. a, Marjan Mansourian Ph.D. a,b, Motahar Heidari-Beni Ph.D. Cand. c,*

a Child Growth and Development Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
b School of Health, Isfahan University of Medical Sciences, Isfahan, Iran
c Food Security Research Center and Department of Community Nutrition, School of Nutrition & Food Science, Isfahan University of Medical Sciences, Isfahan, Iran

A R T I C L E  I N F O
Article history:
Received 21 June 2013
Accepted 17 August 2013

Keywords:
Fructose
Blood glucose
Triglycerides
Lipoproteins
HDL
Blood pressure

A B S T R A C T
Objective: The aim of this study was to review the current corpus of human studies to determine the association of various doses and durations of fructose consumption on metabolic syndrome.

Methods: We searched human studies in PubMed, Scopus, Ovid, ISI Web of Science, Cochrane library, and Google Scholar databases. We searched for the following keywords in each paper: metabolic syndrome x, insulin resistance, blood glucose, blood sugar, fasting blood sugar, triglycerides, lipoproteins, HDL, cholesterol, LDL, blood pressure, mean arterial pressure, systolic blood pressure, diastolic blood pressure, hypertens*, waist circumference, and fructose, sucrose, high-fructose corn syrup, or sugar.

Results: Overall, 3102 articles were gathered. We excluded studies on natural fructose content of foods, non-clinical trials, and trials in which fructose was recommended exclusively as sucrose or high-fructose corn syrup. Overall, 3069 articles were excluded. After review by independent reviewers, 15 studies were included in the meta-analysis. Fructose consumption was positively associated with increased fasting blood sugar (FBS; summary mean difference, 0.307; 95% confidence interval [CI], 0.149–0.465; P = 0.002), elevated triglycerides (TG; 0.275; 95% CI, 0.014–0.408; P = 0.002); and elevated systolic blood pressure (SBP; 0.297; 95% CI, 0.144–0.451; P = 0.002). The corresponding figure was inverse for high-density lipoprotein (HDL) cholesterol (−0.267; 95% CI, −0.406 to −0.128; P = 0.001). Significant heterogeneity existed between studies, except for FBS. After excluding studies that led to the highest effect on the heterogeneity test, the association between fructose consumption and TG, SBP, and HDL became non-significant. The results did not show any evidence of publication bias. No missing studies were identified with the trim-and-fill method.

Conclusion: Fructose consumption from industrialized foods has significant effects on most components of metabolic syndrome.

© 2014 Elsevier Inc. All rights reserved.

Introduction

Fructose is a monosaccharide that naturally exists in fruits, honey, and some vegetables. These days, however, fructose is mostly ingested from industrial and commercial products such as soft drinks, sweetened beverages, and high-fructose corn syrup (HFCS) [1,2]. Natural foods that contain fructose, such as fruits and vegetables, only contain small amounts; moreover their fructose is absorbed slowly. Thus, after consuming these foods, the rise in serum fructose concentration is negligible [3]. The use of HFCS in beverages and soft drinks is increasing by food manufacturers because of its low cost compared with sucrose, and the ease with which it can be added to food products [4]. Actually, the consumption of fructose through manufactured products is concerning. The average daily intake of total fructose in the United Stated increased 12 g/d between 1978 (37 g/d) and 2004 (49 g/d) [5,6].

Fructose is more lipogenic than other carbohydrates, and unlike glucose it can be converted to glycerol-3-phosphate (required for tri-acylglycerol synthesis) without passing from the phosphofructokinase pathway, which is an important rate-limiting pathway of glycolysis. Therefore, high-fructose consumption can be the cause of triglyceride (TG) synthesis from...
unchecked pathways [7]. According to animal studies, consumption of a 60% total energy diet with fructose can induce obesity and some components of metabolic syndrome (MetS) such as insulin resistance, dyslipidemia, and hypertension [8–10].

The escalating trend in the prevalence of chronic diseases in industrialized and developing countries [11] and the increase in fructose consumption in the population’s diet is of concern. Researchers have proposed an association between fructose consumption and chronic diseases [12]. Therefore, many experimental and human studies are being conducted to assess the relationship of fructose consumption with the development of chronic diseases such as diabetes and MetS [4].

Studies of young healthy individuals have shown that fructose consumption (250 g/d) compared with the same amount of glucose significantly decreased insulin sensitivity [7]. There are fewer studies on the long-term effects of fructose consumption on human health than on the effects of glucose [3]. The adverse short-term effects of fructose seem to be dose-dependent. Short-term consumption of fructose in humans did not have adverse effects on health status, unless consumed in excessive amounts. Long-term consumption of fructose is associated with an increase in adiposity, dyslipidemia, and insulin resistance [3,7].

Findings about fructose and health status are controversial. Some studies supported the hypotheses that fructose consumption leads to an increase in chronic disorders such as MetS [13–16], whereas others did not confirm the positive association of fructose with the components of the disease [17–20]. Some reasons may be suggested for the differences between the findings of various studies. Low fructose dose, for instance < 20 g/d, mostly showed improved or no effect on MetS parameters; however, high doses of fructose mostly increased the features of MetS [16,20]. Different forms of fructose such as natural fructose, fructose alone, or fructose bonded with glucose in the form of sucrose, showed various findings [3]. Race, study design, animal or human studies, and different characteristics of participants such as sex, age, and body weight are other factors that influence differences in the findings obtained in various studies.

<table>
<thead>
<tr>
<th>No.</th>
<th>Search terms</th>
</tr>
</thead>
<tbody>
<tr>
<td>3</td>
<td>1 AND 2</td>
</tr>
</tbody>
</table>

Table 1
Search strategy for PubMed, Scopus, Ovid, ISI Web of Sciences, Cochrane library and Google Scholar databases

Fig. 1. Flowchart of the literature search.
<table>
<thead>
<tr>
<th>Reference</th>
<th>Population</th>
<th>Sex</th>
<th>Age (y)</th>
<th>Duration of study</th>
<th>Fructose form and dose</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stanhope et al., 2009</td>
<td>32 overweight and obese participants</td>
<td>Male and female</td>
<td>52.5 ± 8.8</td>
<td>10 wk</td>
<td>Fructose-sweetened beverages provided 25% of energy requirements</td>
<td>Fructose promoted dyslipidemia, increased FBS and insulin levels, and decreased insulin sensitivity</td>
</tr>
<tr>
<td>Swarbrick et al., 2008</td>
<td>7 overweight or obese postmenopausal</td>
<td>Female</td>
<td>64 ± 7.9</td>
<td>10 wk</td>
<td>Fructose-sweetened beverages provided 25% of energy requirements</td>
<td>Fructose increased postprandial TG and fasting apoB concentrations; had no significant effects on fasting total cholesterol, LDL, HDL, TG, or IR</td>
</tr>
<tr>
<td>Perez-Pozo et al., 2010</td>
<td>74 healthy adults</td>
<td>Male</td>
<td>51 ± 7.8</td>
<td>2 wk</td>
<td>Fructose-sweetened beverages, 200 g/d</td>
<td>Fructose led to increased SBP, DBP, fasting TG, fasting insulin, and HOMA indices and decreased HDL cholesterol significantly</td>
</tr>
<tr>
<td>Aeberli et al., 2011</td>
<td>29 healthy, normal-weight (I)</td>
<td>Male</td>
<td>26.3 ± 6.6</td>
<td>3 wk</td>
<td>Fructose-sweetened beverages, 600 mL beverage containing 40 g fructose</td>
<td>FBS increased significantly; SBP, DBP, and postprandial glucose did not change significantly</td>
</tr>
<tr>
<td></td>
<td>29 healthy, normal-weight (II)</td>
<td>Male</td>
<td>26.3 ± 6.6</td>
<td>3 wk</td>
<td>Fructose-sweetened beverages, 600 mL beverage containing 80 g fructose</td>
<td>FBS increased significantly; LDL decreased; SBP, DBP, and postprandial glucose did not change significantly</td>
</tr>
<tr>
<td>Hallfrisch et al., 1983</td>
<td>12 healthy, normal-weight</td>
<td>Male</td>
<td>39.8 ± 2.4</td>
<td>5 wk</td>
<td>15% of calories as fructose</td>
<td>Fructose significantly increased total cholesterol and LDL; did not affect TG level, SBP, or DBP</td>
</tr>
<tr>
<td>Silbernagel et al., 2011</td>
<td>20 healthy, normal-weight</td>
<td>Male and female</td>
<td>32.9 ± 10.5</td>
<td>4 wk</td>
<td>150 g of fructose dissolved in 250 cc water</td>
<td>Plasma NEFA, total cholesterol, LDL cholesterol; HDL cholesterol did not change; insulin sensitivity decreased; TG significantly increased</td>
</tr>
<tr>
<td>Le et al., 2006</td>
<td>7 healthy, normal weight</td>
<td>Male</td>
<td>24.7 ± 1.3</td>
<td>4 weeks</td>
<td>1.5 g fructose/kg BW daily (20% solution)</td>
<td>Fructose led to significant increase in fasting plasma levels of TG, VLDL, lactate, and glucose without causing IR</td>
</tr>
<tr>
<td>Teff et al., 2009</td>
<td>17 obese participants</td>
<td>Male and female</td>
<td>27 ± 2</td>
<td>2 d</td>
<td>Fructose-sweetened beverages (15% solution) provided 30% of energy requirements</td>
<td>Fructose significantly increased FBS, insulin, and TG levels.</td>
</tr>
<tr>
<td>Couchefin et al., 2008</td>
<td>16 healthy, normal weight</td>
<td>Male and female</td>
<td>22.5 ± 0.93</td>
<td>6 d</td>
<td>3.5 g fructose/kg FFM daily (25% of energy requirements)</td>
<td>Fructose increased VLDL, fasting hepatic glucose output; did not change fasting glycemia, insulin</td>
</tr>
<tr>
<td>Sock et al., 2010</td>
<td>11 healthy, normal weight</td>
<td>Male</td>
<td>24.6 ± 0.6</td>
<td>7 d</td>
<td>3.5 g fructose/kg FFM daily (35% of energy requirements)</td>
<td>Postprandial glucose and insulin levels increased slightly; TG level did not change</td>
</tr>
<tr>
<td>Crapo et al., 1984</td>
<td>11 healthy, normal weight</td>
<td>Male and female</td>
<td>40.4 ± 12.4</td>
<td>2 wk</td>
<td>Fructose provided 24% of energy requirements (63–99 g/d)</td>
<td>Fructose reduced insulin sensitivity; FBS did not change</td>
</tr>
<tr>
<td>Bantle et al., 2000</td>
<td>24 healthy, normal weight</td>
<td>Male and female</td>
<td>41.2 ± 14.6</td>
<td>6 wk</td>
<td>Crystalline fructose (14% of energy came from added fructose)</td>
<td>Postprandial glucose and insulin levels increased slightly; TG level did not change</td>
</tr>
<tr>
<td>Bossetti et al., 1984</td>
<td>8 healthy, normal weight</td>
<td>Male and female</td>
<td>27.7 ± 3</td>
<td>14 d</td>
<td>Crystalline fructose (range 50–107 g/d)</td>
<td>Fructose glucose, insulin levels, TG, total cholesterol, LDL, and HDL did not change</td>
</tr>
<tr>
<td>Stanhope et al., 2011</td>
<td>48 healthy participants</td>
<td>Male and female</td>
<td>28.0 ± 6.8</td>
<td>2 wk</td>
<td>Fructose-sweetened beverages provided 25% of energy requirements</td>
<td>Fasting glucose, insulin levels, TG, total cholesterol, LDL, and HDL did not change</td>
</tr>
<tr>
<td>Beck-Nielsen et al., 1980</td>
<td>17 healthy, normal weight</td>
<td>Male and female</td>
<td>28 ± 7</td>
<td>7 d</td>
<td>250 g fructose dissolved in water</td>
<td>Fructose produced 24% of energy requirements (63–99 g/d)</td>
</tr>
<tr>
<td>Stanhope et al., 2008</td>
<td>34 healthy participants</td>
<td>Male and female</td>
<td>34.7 ± 1.7</td>
<td>2 d</td>
<td>Fructose-sweetened beverages provided 25% of energy requirements</td>
<td>There were no significant changes in body weight and plasma concentrations of glucose, insulin, or TG</td>
</tr>
</tbody>
</table>

(Continued on next page)
Table 2 (Continued)

<table>
<thead>
<tr>
<th>Reference</th>
<th>Population</th>
<th>Sex</th>
<th>Duration of study</th>
<th>Fructose form and dose</th>
<th>Results</th>
</tr>
</thead>
</table>
| Cox et al. 2012 [27] | 31 healthy participants | Male and female | 10 wk | Fructose-sweetened beverages provided | Fructose consumption developed risk factors of metabolic syndrome, such as abdominal adiposity, dyslipidemia, and IR. Dietary fructose reduced circulating insulin and increased TG, and increased fasting plasma TC and VLDL.
| Teff et al. 2004 [28] | 12 normal-weight participants | Female | 2 d | Fructose-sweetened beverages provided | Dietary fructose reduced circulating insulin and increased TG.
| Abdel-Sayed et al. 2008 [29] | 6 healthy participants | Male | 24.7 ± 3 | Fructose-sweetened beverages provided | Fructose increased fasting plasma TG (3 g fructose/kg BW daily) concentrations significantly; inhibited lipolysis and lipid oxidation.
| Faeh et al. 2005 [30] | 7 healthy, normal participants | Male | 26.5 ± 4 | Fructose solution (3 g/kg daily, 25% of total calories) | Fructose significantly increased plasma TG concentrations, fasting glyceremia, de novo lipogenesis, and IR.

Keywords such as metabolic syndrome, insulin resistance, blood glucose, blood sugar, fasting blood sugar, triglycerides, lipoproteins, HDL cholesterol, LDL cholesterol, blood pressure, mean arterial pressure, systolic blood pressure, diastolic blood pressure, hypertension, waist circumference, and fructose, sucrose, high-fructose corn syrup, or sugar were used. Keywords and Medical subject heading (MeSH) terms are isolated to the English language. We included human studies and clinical intervention trials that investigated the association of oral fructose on the components of MetS in a healthy population. We did not include animal studies, non-clinical trials, or trials in which fructose was recommended exclusively as sucrose or HFCS because these did not permit us to isolate the effect of fructose. Furthermore, studies that investigated the effect of fructose that is naturally present in fruits, honey, and some vegetables were excluded. The process of selecting studies was showed in Figure 1.

To help clinicians and researchers make decisions when treating their patients, it is necessary to summarize the controversial findings of various studies concerning the health consequences of fructose consumption.

This study aims to review the findings of human studies on the association of fructose consumption with various doses and different duration with MetS.

Methods

Literature search

The search was conducted using PubMed, Scopus, Ovid, ISI Web of Science, Cochrane library, and Google Scholar databases from January to May 2013. Keywords such as metabolic syndrome, insulin resistance, blood glucose, blood sugar, fasting blood sugar, triglycerides, lipoproteins, HDL cholesterol, LDL cholesterol, blood pressure, mean arterial pressure, systolic blood pressure, diastolic blood pressure, hypertension, waist circumference, and fructose, sucrose, high-fructose corn syrup, or sugar were used. Keywords and Medical subject heading (MeSH) terms are isolated to the English language. We included human studies and clinical intervention trials that investigated the association of oral fructose on the components of MetS in a healthy population. We did not include animal studies, non-clinical trials, or trials in which fructose was recommended exclusively as sucrose or HFCS because these did not permit us to isolate the effect of fructose. Furthermore, studies that investigated the effect of fructose that is naturally present in fruits, honey, and some vegetables were excluded. The process of selecting studies was showed in Figure 1.

Titels and abstracts of papers were screened and relevant papers were selected. Then, full texts of relevant papers were read and findings were rescreened. Two independent reviewers (MM and MHB) screened titles and abstracts of papers identified by the literature searches for their potential relevance or assessed the full text for inclusion in the review. Two reviewers abstracted the data independently, including data on first author's last name, year of publication and country of the study population, the study name, study design characteristics, study population, the intervention, outcome measures used, and appropriate statistics, and in the case of disagreement, the discrepancy was resolved in consultation with a third arbitrating investigator (RK). Summary of clinical trials on the association of fructose and components of metabolic syndrome in human studies were shown in Table 2.

Statistical analysis

The groups before and after consuming fructose based on MetS components were compared. Measures of association were used for the meta-analysis: means and SD before and after consuming fructose in all clinical trial studies. We produced funnel plots to assess the multivariate adjusted mean differences and corresponding 95% CIs visually across studies. We used the fixed-effects model for analyses. When heterogeneity existed ($I^2 > 50\%$), we used and compared both random-effect and fixed-effects models. The summary mean difference estimates from random-effect models were used to consider between-study variability, because the tests for heterogeneity were statistically significant in all analyses. Statistical heterogeneity of the statistics between studies was evaluated by Cochran's $Q$ test and $I^2$ statistic [21]. According to the texts, $I^2 > 50\%$ indicated substantial heterogeneity [22]. To identify sources of heterogeneity, sensitivity analysis was done by successively removing a particular study or group of studies (if any) that had the highest impact on the heterogeneity test. Publication bias was assessed by visual inspection of the funnel plot [23]. In these funnel plots; the mean differences were plotted against the inverse of the square of the standard error (a measure of precision). Asymmetry of the funnel plots was assessed formally with Egger’s regression asymmetry tests and adjusted rank-correlation tests [24]. Additionally, Begg’s adjusted rank-correlation test and the trim-and-fill method were used [24,25]. All statistical analyses were done with Comprehensive meta-analysis version 2 software. All $P$-values were two-sided with a significance level $< 0.05$.

Data extraction

Data of articles that investigated the effect of fructose beverage consumption on components of MetS among a healthy adult population were referred to meta-analysis. Mean ± SD of systolic blood pressure (SBP), fasting blood sugar (FBS), high-density lipoprotein cholesterol (HDL-C), and TG before and after fructose consumption were extracted. Some studies expressed changes of MetS components after fructose consumption as changes in area under curves (AUC), another did not reported amount of baseline of these components and some data were unable to be extracted [26–30]. We excluded these studies for meta-analysis. One study [31] used different concentrations of fructose as moderate (40 g/d) and
high (80 g/d) and compared the effect of these concentrations on MetS components. Results of each concentration were interred to meta-analysis separately.

**Results**

**Fructose consumption and FBS**

Individual study results and the overall summary results for the 10 clinical trials investigating the effects of fructose consumption on FBS are shown in Figure 2. When all 10 studies were analyzed, consumption of fructose was positively associated with an increase in FBS (summary mean difference, 0.307; 95% CI, 0.149–0.465; P = 0.002). There was not statistically significant heterogeneity among studies (I² = 43.49%; P heterogeneity = 0.075). The results for random-effect model were 0.357 (95% CI, 0.079–0.63; P = 0.012). Two clinical trials [32,33] contributed the most to heterogeneity. In an analysis excluding these studies, the association between fructose consumption and FBS became slightly weaker (mean difference, 0.285; 95% CI, 0.126–0.444; P = 0.001), and the test for heterogeneity was not statistically significant (I² = 11.7%; P heterogeneity = 0.335).

**Fructose consumption and HDL-C**

Individual study results and the overall summary results for the nine clinical trials that investigated the effects of fructose consumption on HDL-C are shown in Figure 3. When all nine studies were analyzed, consumption of fructose was inversely associated with an increase in HDL-C (summary mean difference, 0.267; 95% CI, 0.079–0.406; P = 0.002). There was not statistically significant heterogeneity among studies (I² = 43.49%; P heterogeneity = 0.075). The results for random-effect model were 0.357 (95% CI, 0.079–0.63; P = 0.012). Two clinical trials [32,33] contributed the most to heterogeneity. In an analysis excluding these studies, the association between fructose consumption and HDL became non-significant (mean difference, 0.008; 95% CI, –0.192 to 0.176; P = 0.932) and the test for heterogeneity was not statistically significant (I² = 19%; P heterogeneity = 0.961).

**Fructose consumption and SBP**

Individual study results and the overall summary results for the 13 clinical trials investigating the effects of fructose consumption on SBP are shown in Figure 4. When all 13 studies were analyzed, fructose consumption was positively associated with increased SBP (summary mean difference, 0.297; 95% CI, 0.144–0.451; P = 0.002). There was statistically significant heterogeneity among studies (I² = 83.36%; P heterogeneity = 0.001). The results for the random-effect model were 0.170 (95% CI, –0.224 to 0.564; P = 0.398). The clinical trial [16] contributed the most to heterogeneity. In an analysis excluding this study, the association between fructose consumption and SBP became non-significant (mean difference, 0.008; 95% CI, –0.192 to 0.176; P = 0.932) and the test for heterogeneity was not statistically significant (I² = 19%; P heterogeneity = 0.961).

**Assessment of publication bias**

Begg’s funnel plot and Egger’s test were conducted to assess the publication bias of the literature. The shape of funnel plots did not reveal any evidence of funnel plot asymmetry. Egger’s test further provided statistical evidence of funnel plot symmetry (fructose consumption and SBP: P = 0.38; fructose consumption and HDL: P = 0.80; fructose consumption and TG: P = 0.20; fructose consumption and FBS: P = 0.21). The results did not show any evidence of publication bias. No missing studies were identified with the trim-and-fill method.

**Discussion**

This meta-analysis showed that fructose consumption has significant adverse effects on FBS. Concerning other components

---

**Fig. 2.** Meta-analysis of the effect of fructose consumption on fasting blood sugar in published clinical trials. The sizes of the data set indicate the weight of each study in the analysis.
of MetS, fructose consumption increased levels of TG and SBP and decreased levels of HDL-C. However, after excluding studies that led to heterogeneity, these adverse effects were not statistically significant. The present study is in agreement with some human and animal studies. Human studies indicated that fructose developed some of the features of MetS as hyper-triglyceridemia, insulin resistance, and abdominal obesity [16,27,30,32,35]. Some animal studies showed a high-fructose diet was associated with hyper-triglyceridemia, impaired glucose tolerance, hyper-insulinemia, insulin resistance, and an increase in blood pressure and body weight [36–39]. These adverse effects were not indicated with equivalent calories of glucose. One study [39] investigated the effects of acute and chronic intake of fructose, finding that both types of fructose intake increased some risks for MetS such as elevated SBP, FBS, and TG concentrations. Some studies reported that 25% or 30% of daily energy requirements that were provided by fructose-sweetened beverages increased TG concentrations [15,28,29], FBS, insulin resistance [30,35], apolipoprotein B [40], SBP, and diastolic blood pressure (DBP) [16], and inhibited lipolysis and lipid oxidation [29]. One study that was conducted on an Iranian population showed fructose intake of >72 g/d and 63 g/d was associated with 11% and 9% enhance risk for hypertension in men and women, respectively [14]. Another study [16] reported that daily intake of 200 g fructose increased SBP and DBP. It was previously reported [12] that fructose intake >50 g/d is associated with the etiologies of MetS.

Previous research found that fructose intake approximately >8% to 12% of energy intake (>50 g/d) is associated with MetS [14]. The researchers found that the amount of fructose intake through fruits and vegetables even in the highest quartile was only 5% of energy (30 g/d). Thus, fructose in industrialized foods is considered the main underlying cause for the increasing risk for MetS.

However, some studies did not find any association between fructose intake and serum cholesterol, uric acid, FBS levels [41], plasma insulin concentration, body weight [37,39], and BP [17].

Heterogeneity between studies was identified statistically. In each analysis, one study was excluded and finally homogeneous studies were found. Factors that led to the highest heterogeneity were differences in experimental design, type, and amount of fructose consumed, characteristics of participants (e.g., being overweight, obese, or normal weight), sex differences, and the study duration. Four studies [16,32–34] had the greatest differences according to these criteria of heterogeneity.

Studies showed free fructose presumably was more dangerous than sucrose on the components of MetS [27]. Fructose is phosphorylated in the liver and is converted to glycerol-3-phosphate. Fructose bypasses the phosphofructokinase pathway, which is the major rate-limiting step of glycolysis. Then it is used for glycerol synthesis or fatty acids through de novo lipogenesis. Conversion of fructose to fatty acid is more rapid than glucose [42]. Furthermore, fructose decreases TG clearance by lipoprotein lipase [43].

Sucrose is composed of one molecule of glucose and fructose. Investigators believe that absorption and metabolism of free fructose is different from fructose contained in sucrose. Serum fructose concentration after sucrose ingestion compared with

---

**Fig. 3.** Meta-analysis of the effect of fructose consumption on HDL-cholesterol in published clinical trials. The sizes of the data set indicate the weight of each study in the analysis.

**Fig. 4.** Meta-analysis of the effect of fructose consumption on blood pressure in published clinical trials. The sizes of the data set indicate the weight of each study in the analysis.
free fructose depends on the activity of intestinal brush-border enzymes to hydrolyze sucrose. Thus, fructose contained in sucrose is absorbed more slowly than fructose ingested as a monosaccharide [3]. Because of these differences in metabolism, we excluded those studies in which fructose was administered as sucrose when isolating and determining the effect of fructose on the components of MetS.

It was documented that the source of fructose might be important in determining the risk for MetS. Natural fructose, for example, the fructose in fruits and vegetables, improved some components of MetS such as elevated BP, blood lipids, insulin resistance, and BMI [44]. Likewise, these beneficial effects were seen with a reduction of diet fructose to < 20 g/d [20]. Fruit consumption enhanced the antioxidant system [13] and decreased the ratio of malondialdehyde to antioxidant capacity [44]. Given that consumption of natural fructose could lead to heterogeneity in our study results, we excluded studies conducted on this type of fructose.

Conclusion

According to our meta-analysis, fructose consumption from industrialized foods, as sweetened beverages, is one of the causes of some chronic disorders as MetS in healthy adults. It provides further support to decrease consumption of fructose-sweetened beverages for the prevention of chronic disorders in a healthy population. However, several studies had investigated the effect of fructose in short-term. Long-term trials in the future about the effect of fructose consumption on chronic diseases can help us to make better decision.

References


Table 1: Study results

<table>
<thead>
<tr>
<th>Study name</th>
<th>Int diff to sucrose</th>
<th>Standard error</th>
<th>Variance</th>
<th>Lower limit</th>
<th>Upper limit</th>
<th>Z-value</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Silventoinen O et al, 2011</td>
<td>0.696</td>
<td>0.208</td>
<td>0.648</td>
<td>0.258</td>
<td>1.141</td>
<td>2.499</td>
<td>0.012</td>
</tr>
<tr>
<td>Strasburger KL et al., 2011</td>
<td>0.277</td>
<td>0.147</td>
<td>0.324</td>
<td>0.012</td>
<td>0.522</td>
<td>2.278</td>
<td>0.023</td>
</tr>
<tr>
<td>Perez-Pozo SS et al, 2010</td>
<td>0.476</td>
<td>0.123</td>
<td>0.573</td>
<td>0.151</td>
<td>0.853</td>
<td>3.573</td>
<td>0.000</td>
</tr>
<tr>
<td>Bok ETN et al, 2010</td>
<td>0.525</td>
<td>0.262</td>
<td>0.535</td>
<td>0.104</td>
<td>0.962</td>
<td>3.857</td>
<td>0.000</td>
</tr>
<tr>
<td>Strasburger KL et al, 2011</td>
<td>-0.125</td>
<td>0.038</td>
<td>-0.395</td>
<td>-0.049</td>
<td>-0.280</td>
<td>-3.299</td>
<td>0.001</td>
</tr>
<tr>
<td>Tell KL et al, 2009</td>
<td>0.101</td>
<td>0.041</td>
<td>0.166</td>
<td>0.002</td>
<td>0.200</td>
<td>2.370</td>
<td>0.019</td>
</tr>
<tr>
<td>Swierwich MD et al, 2008</td>
<td>0.041</td>
<td>0.037</td>
<td>0.143</td>
<td>-0.054</td>
<td>0.142</td>
<td>0.828</td>
<td>0.409</td>
</tr>
<tr>
<td>Cougher C et al, 2008</td>
<td>1.378</td>
<td>0.349</td>
<td>1.622</td>
<td>0.025</td>
<td>1.721</td>
<td>5.404</td>
<td>0.000</td>
</tr>
<tr>
<td>Lo KL et al, 2008</td>
<td>3.938</td>
<td>1.598</td>
<td>2.572</td>
<td>0.546</td>
<td>2.333</td>
<td>2.120</td>
<td>0.035</td>
</tr>
<tr>
<td>Stachowiak J et al, 2009</td>
<td>-0.474</td>
<td>0.236</td>
<td>-0.730</td>
<td>-0.070</td>
<td>-0.295</td>
<td>-3.202</td>
<td>0.001</td>
</tr>
<tr>
<td>Crego PA et al, 1994</td>
<td>-0.139</td>
<td>0.049</td>
<td>-0.372</td>
<td>0.001</td>
<td>-0.095</td>
<td>-2.964</td>
<td>0.003</td>
</tr>
<tr>
<td>Semenic SM et al, 1986</td>
<td>0.460</td>
<td>0.162</td>
<td>0.725</td>
<td>0.005</td>
<td>0.589</td>
<td>2.737</td>
<td>0.006</td>
</tr>
<tr>
<td>Fullrich J et al, 1983</td>
<td>-0.085</td>
<td>0.034</td>
<td>-0.165</td>
<td>0.004</td>
<td>-0.027</td>
<td>-2.550</td>
<td>0.011</td>
</tr>
</tbody>
</table>

Fig. 5. Meta-analysis of the effect of fructose consumption on triglycerides published clinical trials. The sizes of the data set indicate the weight of each study in the analysis.


